Status:
COMPLETED
To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.
Lead Sponsor:
Pfizer
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury.
Eligibility Criteria
Inclusion
- Must have met the inclusion criteria of the preceding double-blind BID study in central pain following spinal cord injury.
- Must have received study medication under double-blind conditions.
Exclusion
- Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT00141375
Start Date
August 1 2002
End Date
January 1 2006
Last Update
January 15 2008
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Little Bay, New South Wales, Australia, 2036
2
Pfizer Investigational Site
St Leonards, New South Wales, Australia, 2065
3
Pfizer Investigational Site
Warrawong, New South Wales, Australia, 2502
4
Pfizer Investigational Site
Woolloongabba, Queensland, Australia, 4102